Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

PEG [SN22]4

Next Previous
X
Search
Drug Profile

PEG [SN22]4

Alternative Names: Camptothecin derivative - PEEL Therapeutics; PEEL-224; Polymer based prodrug of SN22 - PEEL Therapeutics

Latest Information Update: 19 Feb 2025

Price :

$50 *

Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator The Childrens Hospital of Philadelphia
  • Developer PEEL Therapeutics
  • Class Antineoplastics; Camptothecins; Indoles; Piperidines; Small molecules
  • Mechanism of Action DNA topoisomerase I inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Phase I Solid tumours

Most Recent Events

  • 19 Feb 2025 PEG [SN22]4 is available for licensing as of 19 Feb 2025. https://peeltx.com/pipeline/#pipeline-about
  • 06 Dec 2024 Peel Therapeutics plans a phase I/II trial for Solid tumours (Combination therapy, Second-line therapy or greater, In children, In adolescents, In adults) in USA (IV) (NCT06721689)
  • 29 Nov 2024 Dana-Farber Cancer Institute and Peel Therapeutics plans phase-I/II trial for Sarcoma (Second-line therapy or greater, Combination therapy, In adolescents, In adults) in USA (IV, infusion) (NCT06709495),

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top